Evidence map›Paper›PMID 37436162›Full record

ArticleMicrobiology spectrum2023

Vemurafenib Inhibits Acute and Chronic Enterovirus Infection by Affecting Cellular Kinase Phosphatidylinositol 4-Kinase Type IIIβ.

Mira Laajala, Marleen Zwaagstra, Mari Martikainen, Magloire Pandoua Nekoua, Mehdi Benkahla, Famara Sane, Emily Gervais, Grace Campagnola, Anni Honkimaa, Amir-Babak Sioofy-Khojine and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 5 countries.

Mira LaajalaDepartment of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.
Marleen ZwaagstraSection of Virology, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Utrecht University, Utrecht, The Netherlands.
Mari MartikainenDepartment of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.
Magloire Pandoua NekouaLaboratoire de Virologie ULR3610, Université de Lille, CHU Lille, Lille, France.
Mehdi BenkahlaLaboratoire de Virologie ULR3610, Université de Lille, CHU Lille, Lille, France.
Famara SaneLaboratoire de Virologie ULR3610, Université de Lille, CHU Lille, Lille, France.
Emily GervaisDepartment of Biochemistry & Molecular Biology, Colorado State University, Fort Collins, Colorado, USA.
Grace CampagnolaDepartment of Biochemistry & Molecular Biology, Colorado State University, Fort Collins, Colorado, USA.
Anni HonkimaaDepartment of Virology, Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.
Amir-Babak Sioofy-KhojineDepartment of Virology, Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.
Heikki HyötyDepartment of Virology, Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.
Ravi OjhaDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-7876-4607
Marie BailliotDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Giuseppe BalistreriDepartment of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-3585-559X
Olve PeersenDepartment of Biochemistry & Molecular Biology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0001-6208-2660
Didier HoberLaboratoire de Virologie ULR3610, Université de Lille, CHU Lille, Lille, France.
Frank Van KuppeveldSection of Virology, Division of Infectious Diseases & Immunology, Department of Biomolecular Health Sciences, Utrecht University, Utrecht, The Netherlands.
Varpu MarjomäkiDepartment of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.ORCID 0000-0002-4592-5926
Université de Lille · FRColorado State University · USTampere University · FIUniversity of Helsinki · FIUniversity of Jyväskylä · FIUtrecht University · NL

Funding

Assembly of Picornaviral Replication ComplexesR01AI059130 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI PEERSEN, OLVE BREIEN · 2004 to 2021
$4.6M
Assembly of Picornaviral Replication ComplexesR37AI059130 · NIAID · COLORADO STATE UNIVERSITY · PI Olve Breien Peersen · 2023 to 2026
$1.5M
NIAID NIH HHS R01 AI059130NIAID NIH HHS R37 AI059130
6 · The paper itself

Abstract

Enteroviruses are one of the most abundant viruses causing mild to serious acute infections in humans and also contributing to chronic diseases like type 1 diabetes. Presently, there are no approved antiviral drugs against enteroviruses. Here, we studied the potency of vemurafenib, an FDA-approved RAF kinase inhibitor for treating BRAF

Indexed as

EnterovirusEnterovirus InfectionsMelanoma1-Phosphatidylinositol 4-KinaseAnimalsHumansMiceMitogen-Activated Protein Kinase KinasesMutationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafVemurafenib1-Phosphatidylinositol 4-KinaseMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafVemurafenibacute infectionantiviralchronic infectiondrug repurposingenterovirus

Identifiers

PMID37436162
PMCPMC10433971
OpenAlexW4383998815

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.